Novartis scoops up IFM immunotherapy subsidiary for $310 million
April 01, 2019 at 01:16 AM EDT
Pharmaceutical giant Novartis will pay $310 million to purchase an Atlas Venture-backed Boston startup focused on treatments using the body's immune system.
